Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer appointment

This article was originally published in The Tan Sheet

Executive Summary

Barbara Korberly named VP-clinical research & medical affairs activities for the Morristown, N.J.-based R&D unit, Bayer Consumer Care announces April 14. She also will lead the firm's aspirin cardio-prevention projects; Bayer recently filed a citizen petition with the FDA requesting clearance to label aspirin with claims for primary prevention of myocardial infarction (1"The Tan Sheet" Feb. 17, 2003, p. 3). Korberly joins Bayer from Pharmacia, where she served as head of global medical...

You may also be interested in...



Aspirin MI Primary Prevention Labeling Urged In Bayer Citizen Petition

Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.

Topics

UsernamePublicRestriction

Register

PS095361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel